Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7644614 | 0.82 | TP53 (0.46) | TP53TSHRALOX15ALOX12LDHA | |
| SCHEMBL17693614 | 0.78 | TP53 (0.43) | TP53TSHRCARM1PRMT6ALOX15 | |
| SCHEMBL7770130 | 0.78 | ESR1 (0.42) | S1PR2S1PR1S1PR3LPAR2CARM1 | |
| SCHEMBL29781139 | 0.76 | TP53 (0.53) | TP53TSHRALOX15ALOX12NPSR1 | |
| SCHEMBL25395008 | 0.76 | TP53 (0.53) | TP53TSHRALOX15ALOX12NPSR1 | |
| SCHEMBL17693594 | 0.72 | ESR1 (0.53) | TP53TSHRALOX15ALOX12 | |
| SCHEMBL2785384 | 0.72 | TP53 (0.49) | TP53TSHRS1PR1SMN1; SMN2 | |
| SCHEMBL5792794 | 0.72 | LDHA (0.58) | TP53TSHRALOX15ALOX12LDHA | |
| SCHEMBL27406562 | 0.71 | LMNA (0.47) | LDHA | |
| SCHEMBL27406535 | 0.69 | FFAR4 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | ABBVIE INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20180079762-A1 | Carbidopa and L-Dopa Prodrugs and Methods of use | ABBVIE INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20160362431-A1 | Carbidopa And L-Dopa Prodrugs And Methods Of Use | ABBVIE INC. | 2016-12-15 | — | — | US | disclosed |
| US-9446059-B2 | Carbidopa and L-dopa prodrugs and methods of use | ABBVIE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160106765-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | ABBVIE INC. | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362431-A1 | Carbidopa And L-Dopa Prodrugs And Methods Of Use | COMT, SNCA, PARK7 | TP53 1495/4885TSHR 1816/4885S1PR2 1871/4885 |
| US-20160106765-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | COMT, SNCA, PARK7 | TP53 1495/4885TSHR 1816/4885S1PR2 1871/4885 |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | COMT, SNCA, PARK7 | TP53 1495/4885TSHR 1816/4885S1PR2 1871/4885 |
| US-20180079762-A1 | Carbidopa and L-Dopa Prodrugs and Methods of use | COMT, SNCA, PARK7 | TP53 1495/4885TSHR 1816/4885S1PR2 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.